Ischemic Stroke Pipeline Experiences Rapid Expansion as Over 50+ Leading Companies Advance Novel Therapies

DelveInsight's, "Ischemic Stroke Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ischemic Stroke pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Ischemic Stroke Pipeline. Dive into DelveInsight's comprehensive report today! @ Ischemic Stroke Pipeline Outlook [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Ischemic Stroke Pipeline Report

* In July 2025, EIP Pharma Inc . announced a study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
* In July 2025, Pharmazz Inc . conducted a phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States.
* In July 2025, DiaMedica Therapeutics Inc . conducted a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation.
* DelveInsight's Ischemic Stroke pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Ischemic Stroke treatment.
* The leading Ischemic Stroke Companies such as Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Promising Ischemic Stroke Pipeline Therapies such as Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.

Stay ahead with the most recent pipeline outlook for Ischemic Stroke. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Ischemic Stroke Treatment Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ischemic Stroke Emerging Drugs Profile

* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine

Milvexian (BMS-986177) (Factor XIa) is an investigational anticoagulant compound. Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway. A small study of Hemophilia C patients showed a lower risk of stroke. The drug is being developed by Bristol-Myers Squibb in collaboration with Johnson & Johnson. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke.

* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.

XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03-EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose-dependent way. Mechanistically, XY03-EA inhibited ROS-dependent autophagy activation and thereby protected the PC-12 cells from the autophagic cell death induced by OGD/R. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

* NONO-42: NoNO Inc.

NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Of the 650,000 people experiencing an acute ischemic stroke treated annually in US hospitals, approximately 10% receive a thrombolytic, which may reduce the applicability of nerinetide. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase II stage of its development for the treatment of acute ischemic stroke.

* hNPC01: Hopstem Biotechnology

hNPC01 refers to a novel cell therapy utilizing human induced pluripotent stem cell (iPSC)-derived human forebrain neural progenitor cells aimed at treating ischemic stroke. This therapy is particularly significant as it represents the first iPSC-derived product to receive FDA Investigational New Drug (IND) clearance for stroke treatment. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.

The Ischemic Stroke Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
* Ischemic Stroke Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market

Explore groundbreaking therapies and clinical trials in the Ischemic Stroke Pipeline. Access DelveInsight's detailed report now! @ New Ischemic Stroke Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ischemic Stroke Companies

Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Ischemic Stroke Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Ischemic Stroke Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Ischemic Stroke Market Drivers and Barriers [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Ischemic Stroke Pipeline Report

* Coverage- Global
* Ischemic Stroke Companies- Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Ischemic Stroke Pipeline Therapies- Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.
* Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Ischemic Stroke Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Ischemic Stroke Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Ischemic Stroke: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ischemic Stroke- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* hNPC01: Hopstem Biotechnology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Ischemic Stroke Key Companies
* Ischemic Stroke Key Products
* Ischemic Stroke- Unmet Needs
* Ischemic Stroke- Market Drivers and Barriers
* Ischemic Stroke- Future Perspectives and Conclusion
* Ischemic Stroke Analyst Views
* Ischemic Stroke Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ischemic-stroke-pipeline-experiences-rapid-expansion-as-over-50-leading-companies-advance-novel-therapies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.